GH1 and neoplasm: About 90% of GH-producing PitNETs express SSTR2 and SSTR5 which are targeted by somatostatin analogues (SSA), when intervention fails to control tumour activity dopamine agonists (DA) that target dopamine receptor 2 (D2R) are introduced to improve disease management [9].